Search results for " Fluticasone furoate"

showing 2 items of 2 documents

Fluticasone furoate maintains epithelial homeostasis via leptin/leptin receptor pathway in nasal cells

2014

Leptin is involved in the lung epithelial homeostasis. Its role in the nasal tract is largely unknown. Allergic rhinitis (AR) is induced by the allergen exposure leading to consequential structural abnormalities in the nasal epithelium. Topical corticosteroids are recommended as first-line therapy in AR. Parietaria pollen is one of the most important allergenic sources in the southern Europe. In vitro, in human nasal epithelial cell line RPMI 2650, we aimed to determine whether allergen stimulation acts on leptin/leptin receptor pathway and how fluticasone furoate (FF) influences this pathway. The effects of the major allergen recombinant Par j 1 (rPar j 1), of FF, of leptin, and of TGF-b1 …

LeptinSTAT3 Transcription Factormedicine.medical_specialtyAllergic rhinitis Epithelium Fluticasone furoate Leptin rPar j 1Clinical BiochemistryStimulationSettore MED/10 - Malattie Dell'Apparato RespiratorioBiologymedicine.disease_causeSettore BIO/09 - FisiologiaFluticasone propionateCell LineTransforming Growth Factor beta1AllergenWestern blotAllergic rhinitis Epithelium Fluticasone furoate Leptin rPar j 1Internal medicinemedicineHomeostasisHumansMolecular BiologyCell ProliferationPlant ProteinsLeptin receptormedicine.diagnostic_testCell growthLeptindigestive oral and skin physiologyCell BiologyGeneral MedicineAllergensRhinitis AllergicEpitheliumRecombinant ProteinsAndrostadienesNasal MucosaProtein TransportEndocrinologymedicine.anatomical_structureReceptors Leptinhormones hormone substitutes and hormone antagonistsmedicine.drugSignal Transduction
researchProduct

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

2017

BACKGROUNDPatients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.METHODSWe performed two phase 3, randomized, placebo-controlled, double-blind, parallel-group trials comparing mepolizumab (100 mg in METREX, 100 or 300 mg in METREO) with placebo, given as a subcutaneous injection every 4 weeks for 52 weeks in patients with COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy. In METREX, unselected patients in the modified intention-to-treat population with an eosinophilic phenotype were …

medicine.medical_specialtyPARALLEL-GROUPPopulationPlacebo-controlled studyPNEUMONIA RISKPlaceboPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health sciencesDOUBLE-BLIND0302 clinical medicineMaintenance therapyInternal medicineEosinophilicmedicineINHALED FLUTICASONE FUROATE030212 general & internal medicineeducationCOPDeducation.field_of_studyIntention-to-treat analysisCOPD ASSESSMENT TESTSPUTUM EOSINOPHILIAbusiness.industryGeneral MedicineRANDOMIZED CONTROLLED-TRIALBLOOD EOSINOPHILSmedicine.diseaseSECONDARY ANALYSIS030228 respiratory systemImmunologybusinessMepolizumabmedicine.drug
researchProduct